Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nanobiotix ( (NBTX) ) just unveiled an update.
On May 14, 2025, Nanobiotix announced its updated share capital and voting rights information, reflecting 47,426,851 shares outstanding and 49,513,765 exercisable voting rights as of April 30, 2025. This update is crucial for stakeholders to understand the company’s current equity structure and voting power distribution, potentially impacting future shareholder meetings and decisions.
The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Underperform.
Nanobiotix’s stock is rated low due to significant financial instability, negative profitability, and a lack of clear technical momentum. Strategic partnerships and pipeline developments provide some optimism, but the company’s immediate financial hurdles and valuation concerns weigh heavily on the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, focusing on innovative, physics-based therapeutic approaches. Founded in 2003, the company is listed on Euronext Paris and Nasdaq, and holds over 25 patent families related to oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 11,300
Technical Sentiment Signal: Sell
Current Market Cap: $163.9M
For detailed information about NBTX stock, go to TipRanks’ Stock Analysis page.